differ
continu execut well management slightli lower
humira guidanc remain confid upadacitinib
safeti profil rais ep lower pt due
grow humira headwind expect constrain
rais ep lower pt increas ep
lower pt old
ep new expect grow
financi percept pressur franchis humira pt
base case ep peer median due flat long-term ep
growth risk long-term humira declin next decad driver
pt reduct fda indic file key cancer pipelin asset rova-t
fda commission gottlieb biosimilar initi may result greater
pressur drug humira long term estim revis new vs old vs
ceo gonzalez explain co-pay accumul pressur us humira
management lower us humira guidanc yoy
yoy due retail specialti pharmaci destock well moder
conserv stanc co-pay cost associ cost accumul program
certain high deduct commerci plan gonzolaz state
us popul subject co-pay accumul program block
manufactur co-pay assist count toward patient deduct
out-of-pocket maximum estim us popul high
deduct health plan accumul program
gonzalez said sinc patient use chronic drug opt
high deduct plan futur impact program could decreas
next year think countri high deduct health plan could
adopt co-pay accumul
manag assumpt vs project ex-u humira biosimilar
set launch europ shortli thereaft management estim
declin ex-u humira rel conserv
estim estimate base sale declin
although management anticip soften pressur
sinc largest re-set price occur fear ex-u volum
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pressur could grow europ drive greater biosimilar adopt
analyz ex-u brand remicad brand enbrel declinesse
biosimilar impact remicad enbrel ex-u note figur adjust
impact fx rel situat good news
humira demand growth current higher product experienc
biosimilar entri bad news biosimilar could enter
humira shortli patent expiri sandoz bi fourth player could
launch next winter other could subsequ follow
upadacitinib figur provid head michael severino appear
encourag data need state control
period clinic trial five case dvt/pe upadacitinb vs
four control therefor see imbal also
emphas modest decreas platelet week return baselin
timeand impli better platelet impact profil lilli baricitinib
need comprehens data dvt/pe event rel placebo includ
select-earli trial comprehens dvt/pe safeti
review thereaft jak baricitinib fda action
pt base base case ep
peer median due flat long-term ep growth risk
long-term humira declin next decad
bull case ep
bull case ep
humira imbruvica sale exceed estim drive ep
term growth driver add new revenu driver diversifi beyond
humira help price-to-earnings
base case ep
base case ep
see balanc risk-reward expect strong ep growth posit
pipelin develop near-term balanc long-term humira biosimilar
threat includ risk us biosimilar interchang
bear case ep
bear case ep
earn newsflow concern humira imbruvica sale
disappoint caus ep forecast pipelin candid disappoint
 jak due blood clot risk biosimilar humira threat includ neg
patent news interchang progress caus concern
equal-weight share
robust ep growth
growth near-medium term
balanc risk price-to-earnings contract long term
us biosimilar humira entri approach
near-medium term roll us
like pursu extern
transact enhanc pipelin
biosimilar anti-tnf remicad
humira imbruvica sale trends/outlook
financi result rel expect
extern busi develop
risk achiev price
upsid risk result
posit humira patent news value-
downsid risk result
disappoint problemat legal
biosimilar impact remicad enbrel ex-u
first remicad biosimilar launch first
enbrel biosimilar launch
exhibit remicad enbrel ex-u sale declin yoy sinc biosimilar enter figur
adjust fx impact
price
price
price
exhibit trade mean year histor mean
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
